Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 291 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR 如果您剛確診為肺癌患者，請來看看專家的回答 April 22, 2021 What Latino People Should Know About Quitting Smoking and Health Disparities:... November 18, 2021 Whipple Procedure for Pancreatic Cancer: How to Prepare and What to... September 16, 2021 FDA Approvals Bring New Options for Older Patients with AML December 27, 2018 Load more HOT NEWS Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... Doctors Think Woman Has A Brain Tumor, But Then They Open... EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab Experts Think Medical Detection Dogs Could Be Trained To Sniff Out...
